Form 4: Q32 Bio Inc. CEO Jodie Pope Morrison Reports Changes in Beneficial Ownership After Option Repricing

CEO Jodie Pope Morrison reports changes in beneficial ownership of Q32 Bio Inc. stock and options following an option repricing approved by the board of directors.

Summary

• On February 24, 2025, Jodie Pope Morrison, CEO of Q32 Bio Inc., reported changes in beneficial ownership.
• These changes include the acquisition of 132,000 shares of common stock and adjustments to stock options.
• The Issuer's board of directors approved an option repricing on February 24, 2025.
• The repricing affected multiple stock option grants with varying exercise prices and expiration dates.
• Morrison's holdings include direct ownership of common stock and stock options.
• The reported transactions involve options with exercise prices of $7.5, $2.54, and $17.08.
• The expiration dates for these options range from November 8, 2033, to March 24, 2034.
• Restricted stock units (RSUs) vest in four equal installments over 36 months from the grant date of February 24, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports transactions and an option repricing, which is neither inherently positive nor negative. The impact depends on the company's future performance.

Positives

• The option repricing could incentivize the CEO to improve company performance.
• The CEO's continued holding of stock options and shares aligns her interests with those of shareholders.

Risks

• The repricing of options could be perceived negatively by shareholders if not accompanied by improved company performance.
• The vesting schedule of the RSUs and options could delay the CEO's realization of value, potentially impacting motivation.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of RSUs and options suggests a multi-year commitment from the CEO.

Industry Context

Option repricing is a tool companies use to re-incentivize executives when the stock price has declined. It's common in the biotech industry, which is subject to high volatility and long development timelines.

Comparison to Industry Standards

• Option repricing is a common practice in the biotech industry, particularly for companies with long development cycles.
• Comparing Q32 Bio's repricing terms (exercise price, vesting schedule, etc.) to those of similar-stage biotech companies (e.g., those in the XBI ETF) could provide context on whether the terms are favorable or unfavorable.
• Companies like CRISPR Therapeutics and Editas Medicine have also used option repricing to retain and incentivize key executives.

Stakeholder Impact

• Shareholders may view the option repricing as a positive if it leads to improved company performance and increased stock value.
• Employees may be affected by the option repricing if they also hold stock options, as it could impact their potential compensation.

Key Dates